The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of CorMedix, Inc. ("CorMedix") (NYSE MKT: CRMD) between March 12, 2011 and June 29, 2015 .

You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. If you purchased or otherwise acquired CorMedix, Inc. securities between March 12, 2011 and June 29, 2015, your rights may be affected by this action. To get more information go to:

or contact Joseph E. Levi, Esq. either via email at or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, among other allegations, during the Class Period defendants' overstated the cost effectiveness and effectiveness of Neutrolin compared to currently established medical protocol, failed to disclose the use of paid stock promoters, and that insiders enriched themselves at the expense of shareholders by selling stock at inflated prices.

On June 29, 2015, an article by The Pump Stopper and featured on Seeking Alpha alleged that personnel involved in the formation of CorMedix had faced prior accusations of fraud, that Neutrolin's performance in clinical trials was vastly overstated, and that the Company had engaged stock promoters in order to inflate the Company's share price.

If you suffered a loss in CorMedix you have until September 4, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on

Copyright Business Wire 2010